New York (AFP) – Pfizer forecast more than $50 billion in 2022 sales for its Covid-19 vaccine and therapeutic on Tuesday as the giant pharma company reported a more than doubling of annual profits on strong vaccine sales. Pfizer, which with German company BioNTech won approval for the first vaccine to counter the deadly virus, sees slightly lower 2022 revenues for the vaccine compared the just-finished year, but a big infusion of revenues from Paxlovid, the company’s pill for Covid-19. “2021 was a watershed year for Pfizer,” said Chief Executive Albert Bourla in a statement. “Our successes in …